Galapagos NV
AEX:GLPG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.12
38.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Galapagos NV
Galapagos NV
Total Current Liabilities
Galapagos NV
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galapagos NV
AEX:GLPG
|
Total Current Liabilities
€364.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Total Current Liabilities
$45m
|
CAGR 3-Years
55%
|
CAGR 5-Years
41%
|
CAGR 10-Years
25%
|
|
|
Oxurion NV
XBRU:OXUR
|
Total Current Liabilities
€12.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Total Current Liabilities
€2.9m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Galapagos NV
Glance View
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 1,309 full-time employees. The company went IPO on 2005-05-06. The firm is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
See Also
What is Galapagos NV's Total Current Liabilities?
Total Current Liabilities
364.8m
EUR
Based on the financial report for Sep 30, 2024, Galapagos NV's Total Current Liabilities amounts to 364.8m EUR.
What is Galapagos NV's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-10%
Over the last year, the Total Current Liabilities growth was -18%. The average annual Total Current Liabilities growth rates for Galapagos NV have been -14% over the past three years , -10% over the past five years .
You don't have any saved screeners yet
